On May 31, 2024 Agendia, Inc. reported it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens at the 2024 Annual American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Meeting, taking place in Chicago, IL. on May 31st, 2024 (Press release, Agendia, MAY 31, 2024, View Source [SID1234643916]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data will be presented in an oral discussion by Joyce O’Shaughnessy MD, Director, Breast Cancer Research, Baylor University Medical Center, Texas Oncology and the Sarah Cannon Research Institute in Dallas, TX, Primary Investigator of the FLEX Study, titled Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline [O’Shaughnessy, J., et al.]. The FLEX study investigates the 3-year outcome of patients with HR+HER2-, genomically High Risk Luminal B-Type early breast cancer, who have undergone treatment consisting of chemotherapy with taxane and cyclophosphamide (TC) or chemotherapy with anthracycline + TC (AC-T). All patients are enrolled in the prospective, non-randomized, observational FLEX Study (NCT03053193). This study utilized both MammaPrint and BluePrint to determine tumor subtype.

Results showed that patients with MammaPrint H1 Luminal B-Type tumors demonstrated similar 3-year outcomes when treated with either TC (97.1%) or AC-T (95.3%), suggesting that patients who are classified as H1 may be able to avoid the toxicity of an anthracycline. However, patients with MammaPrint H2 Luminal B-Type tumors demonstrated a significantly higher relapse-free survival when treated with AC-T (97.7%) than with TC alone (86.4%). These findings indicate that MammaPrint H2 tumors benefit from the addition of an anthracycline to their adjuvant chemotherapy regimen.

"The ability to tailor treatment regimens to a patient’s tumor biology is crucial to optimize outcomes and quality of life. MammaPrint’s utility in guiding treatment planning is highlighted by these new data evaluating chemotherapy selection," said Dr. O’Shaughnessy. "The FLEX Study and sub-studies, such as this one, enable increased precision in identifying patients that are more responsive to specific systemic therapy regimens, and continue to aid selection of treatments for patients with HR+/HER2-negative early-stage breast cancer."

"These new findings demonstrate the strength of the FLEX research platform in evaluating the different aspects of breast cancer during its diagnosis and treatment stages, allowing for more precise and individualized treatment recommendations," said William Audeh, MD, Chief Medical Officer at Agendia. "This study offers a preliminary signal towards groundbreaking insight into MammaPrint High Risk tumors and how they best respond to chemotherapy regimens, underscoring the clinical utility of MammaPrint in the selection of treatment. We remain committed to advancing breast cancer research to help deliver the best standard of practice to women undergoing breast cancer care."

Additional data supporting MammaPrint utility in treatment selection will be presented by investigators from the ISPY2 trial in a poster titled Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancer Closely Resembles Triple Negative Breast Cancer: Results from Gene Expression Data from the ISPY2 Trial [Rios-Hoyo, A., et al.]. By using data from the ISPY-2 trial, this poster demonstrates that MammaPrint H2 tumors have molecular and clinical similarities to triple negative breast cancer tumors, underscoring critical insight into how treatment plans can be optimized to achieve the best result for the patient.

Agendia will be sharing updates throughout the conference on its Twitter, Facebook and LinkedIn pages.